All In Biotech

BLA 021148 · Novo Nordisk INC

Norditropin Flexpro

Somatropin · Injection · Recombinant Human Growth Hormone

Orphan

Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Jun 20, 2000

Approved uses

7

Original approval plus efficacy supplements

Registered trials

540

176 Phase 3, 31 recruiting

FAERS reports

9,514

6,529 serious, 504 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 7, 2025.

NORDITROPIN is a recombinant human growth hormone indicated for: • Pediatric : Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Noonan syndrome, short stature associated with Turner syndrome, short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4 years, Idiopathic Short Stature (ISS), and growth failure due to Prader-Willi Syndrome ( 1.1 ) • Adult : Replacement of endogenous GH in adults with growth hormone deficiency ( 1.2 ) 1.1 Pediatric Patients NORDITROPIN is indicated for the treatment of pediatric patients with: • growth failure due to inadequate secretion of endogenous growth hormone (GH), • short stature associated with Noonan syndrome, • short stature associated with Turner syndrome, • short stature born small for gestational age (SGA) with no catch-up growth by age 2 years to 4 years of age, • Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, • growth failure due to Prader-Willi syndrome (PWS). 1.2 Adult Patients NORDITROPIN is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD)

Mechanism: Somatropin binds to dimeric GH receptors located within the cell membranes of target tissue cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or mediated indirectly by IGF-1, including stimulation of chondrocyte differentiation, and proliferation, stimulation hepatic glucose output, protein synthesis and lipolysis. Somatropin stimulates skeletal growth in pediatric patients with GHD as a...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

11 products under this application
  • NORDITROPIN FLEXPRO · SOMATROPIN 5MG/1.5ML · INJECTABLE, INJECTION · Prescription
  • NORDITROPIN NORDIFLEX · SOMATROPIN 15MG/1.5ML · INJECTABLE, INJECTION · Discontinued
  • NORDITROPIN NORDIFLEX · SOMATROPIN 5MG/1.5ML · INJECTABLE, INJECTION · Discontinued
  • NORDITROPIN FLEXPRO · SOMATROPIN 15MG/1.5ML · INJECTABLE, INJECTION · Prescription
  • NORDITROPIN · SOMATROPIN 10MG/1.5ML · INJECTABLE, INJECTION · Discontinued
  • NORDITROPIN FLEXPRO · SOMATROPIN 10MG/1.5ML · INJECTABLE, INJECTION · Prescription
  • NORDITROPIN NORDIFLEX · SOMATROPIN 30MG/3ML · INJECTABLE, INJECTION · Discontinued
  • NORDITROPIN NORDIFLEX · SOMATROPIN 10MG/1.5ML · INJECTABLE, INJECTION · Discontinued
  • NORDITROPIN FLEXPRO · SOMATROPIN 30MG/3ML · INJECTABLE, INJECTION · Prescription
  • NORDITROPIN · SOMATROPIN 15MG/1.5ML · INJECTABLE, INJECTION · Discontinued
  • NORDITROPIN · SOMATROPIN 5MG/1.5ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Somatropin" as an intervention, any sponsor and status, largest first.

All 540 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use555
  • headache406
  • device leakage347
  • injection site pain302
  • fatigue262
  • drug dose omission by device233
  • drug ineffective233
  • death204
  • pyrexia202
  • product dose omission issue187
  • vomiting185
  • nausea184

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200467
200535
200644
2007149
200899
2009276
2010216
2011253
2012297
2013145
2014257
2015371
2016551
2017477
2018553
2019726
2020658
2021545
2022743
2023991
2024879
2025672
2026510

Recalls

1 FDA enforcement reports for this application.

  • Apr 27, 2016 · Class II · Terminated

    Defective Delivery System; may have a low frequency assembly fault which may result in pens block during the so-called "air shot" step

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Norditropin Flexpro (Somatropin)

2024 spending

$16.4M

Beneficiaries

779

4,541 claims

Per beneficiary

$21,033

$1,069.83 per unit

View as table
YearSpending
2020$17,154,790
2021$16,743,673
2022$17,359,212
2023$11,093,988
2024$16,384,406

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 83 on PubMed

Sponsor: Novo Nordisk · Also marketed as Norditropin Nordiflex, Norditropin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.